Company Updates - Colin Campbell has stepped down as CEO after successfully repositioning the company for future success and retiring the debenture He will remain as a Director and assist in identifying a new CEO to lead the company through the clinical testing phase and commercialization of its proprietary biomarker test for depression [1] - The company successfully retired its debenture removing $3 5 million (CDN) of debt from its balance sheet This milestone reflects the company's strategic focus on developing the first depression biomarker test [4][5] Company Overview - MYND Life Sciences Inc is a clinical-stage life sciences company focused on developing and commercializing a proprietary biomarker test for diagnosing and monitoring Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD) The company aims to be the first to market with this innovative test addressing a significant unmet need in depression management [2] - The company's proprietary biomarker test leverages unique intellectual property (IP) and has the potential to generate near-term revenues by driving personalized patient management strategies [2]
MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition